Year Founded
2016
Ownership
Public
Stage
Phase 3
Modalities
Small molecule

Dova Pharmaceuticals General Information

Completed two Phase 3 trials (ADAPT 1 and ADAPT 2) for avatrombopag in thrombocytopenia in CLD patients undergoing procedures. Met primary and secondary endpoints with high statistical significance. Planning NDA submission in Q3 2017.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Durham, North Carolina
United States

Drug Pipeline

avatrombopag
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Dova Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Eisai, Astellas

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Dova Pharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Dova Pharmaceuticals's complete valuation and funding history, request access »

Dova Pharmaceuticals Investors

PBM Capital
Investor Type: Venture Capital
Holding: Minority